Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 2
2013 1
2014 2
2018 1
2019 4
2020 2
2022 1
2023 2
2024 2
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management.
Yazdani R, Fekrvand S, Shahkarami S, Azizi G, Moazzami B, Abolhassani H, Aghamohammadi A. Yazdani R, et al. Clin Immunol. 2019 Jan;198:19-30. doi: 10.1016/j.clim.2018.11.007. Epub 2018 Nov 13. Clin Immunol. 2019. PMID: 30439505 Review.
Hyper Immunoglobulin M syndrome (HIGM) is a rare primary immunodeficiency disorder characterized by low or absent levels of serum IgG, IgA, IgE and normal or increased levels of serum IgM. ...
Hyper Immunoglobulin M syndrome (HIGM) is a rare primary immunodeficiency disorder characterized by low or absent levels of serum IgG …
Results From a Randomized Trial of Intensive Glucose Management Using CGM Versus Usual Care in Hospitalized Adults With Type 2 Diabetes: The TIGHT Study.
Hirsch IB, Draznin B, Buse JB, Raghinaru D, Spanbauer C, Umpierrez GE, Ullal J, Jones MS, Low Wang CC, Spanakis EK, Chao JH, Sibayan J, Kollman C, Zabala ZE, Moazzami B, Reynolds SL, Ferrara W, Fulghum K, Kass A, Armstrong C, Gilani F, Seggelke S, Churchill J, Monye JO, Choe MY, Scott W, Baran JD, Bais R, Khakpour D, Pasquel FJ, Davis GM, Vellanki P, Kershaw EE, Gligorijevic N, Goley A, Garg A, Alexander B, Matson BC, Diner J, Klein KR, Adair WB, Choksi P, Huang M, Vinh J, Singh LG, Beck RW; TIGHT RCT Study Group. Hirsch IB, et al. Diabetes Care. 2025 Jan 1;48(1):118-124. doi: 10.2337/dc24-1779. Diabetes Care. 2025. PMID: 39571106 Free PMC article. Clinical Trial.
Clinical Manifestations, Immunological Characteristics and Genetic Analysis of Patients with Hyper-Immunoglobulin M Syndrome in Iran.
Tafakori Delbari M, Cheraghi T, Yazdani R, Fekrvand S, Delavari S, Azizi G, Chavoshzadeh Z, Mahdaviani SA, Ahanchian H, Khoshkhui M, Behmanesh F, Aleyasin S, Esmaeilzadeh H, Jabbari-Azad F, Fallahpour M, Zamani M, Madani SP, Moazzami B, Habibi S, Rezaei A, Lotfalikhani A, Movahed M, Shariat M, Kalantari A, Babaei D, Darabi M, Parvaneh N, Rezaei N, Abolhassani H, Aghamohammadi A. Tafakori Delbari M, et al. Int Arch Allergy Immunol. 2019;180(1):52-63. doi: 10.1159/000500197. Epub 2019 May 22. Int Arch Allergy Immunol. 2019. PMID: 31117086
BACKGROUND: Hyper-immunoglobulin M (HIGM) syndrome is a rare heterogeneous group of primary immunodeficiency disorders characterized by low or absent serum levels of IgG and IgA along with normal or elevated serum levels of IgM. ...
BACKGROUND: Hyper-immunoglobulin M (HIGM) syndrome is a rare heterogeneous group of primary immunodeficiency disorders characterized …
Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia.
Moazzami K, Moazzami B, Roohi A, Nedjat S, Dolmatova E. Moazzami K, et al. Cochrane Database Syst Rev. 2014 Dec 19;2014(12):CD008347. doi: 10.1002/14651858.CD008347.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2022 Jul 8;7:CD008347. doi: 10.1002/14651858.CD008347.pub4. PMID: 25525690 Free PMC article. Updated.
The treatment group experienced a statistically significant increase in pain-free walking distance (PFWD) compared with the control group (mean increase 306.4 m versus 78.6 m, P = 0.007). A smaller proportion of participants underwent amputation in the treatment gro …
The treatment group experienced a statistically significant increase in pain-free walking distance (PFWD) compared with the control group (m …
Respiratory Complications in Patients with Hyper IgM Syndrome.
Moazzami B, Yazdani R, Azizi G, Kiaei F, Tafakori M, Modaresi M, Shirzadi R, Mahdaviani SA, Sohani M, Abolhassani H, Aghamohammadi A. Moazzami B, et al. J Clin Immunol. 2019 Aug;39(6):557-568. doi: 10.1007/s10875-019-00650-3. Epub 2019 Jun 11. J Clin Immunol. 2019. PMID: 31183658
PURPOSE: Hyper Immunoglobulin M (HIgM) syndrome is a heterogeneous group of primary immunodeficiency disorders, characterized by recurrent infections and associated with decreased serum IgG and IgA, but normal or increased IgM. ...
PURPOSE: Hyper Immunoglobulin M (HIgM) syndrome is a heterogeneous group of primary immunodeficiency disorders, characterized by recu …
Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia.
Moazzami K, Majdzadeh R, Nedjat S. Moazzami K, et al. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008347. doi: 10.1002/14651858.CD008347.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2014 Dec 19;(12):CD008347. doi: 10.1002/14651858.CD008347.pub3. PMID: 22161427 Updated.
The treatment group experienced a statistically significant increase in pain-free walking distance compared with the control group (mean increase 306.4 m versus 78.6 m, P = 0.007). A smaller proportion of participants underwent amputation in the treatment group comp …
The treatment group experienced a statistically significant increase in pain-free walking distance compared with the control group (mean inc …
A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.
Galindo RJ, Moazzami B, Scioscia MF, Zambrano C, Albury BS, Saling J, Vellanki P, Pasquel FJ, Davis GM, Fayfman M, Peng L, Umpierrez GE. Galindo RJ, et al. Diabetes Care. 2023 Sep 1;46(9):1640-1645. doi: 10.2337/dc22-2426. Diabetes Care. 2023. PMID: 37459574 Free PMC article. Clinical Trial.
Circulating Progenitor Cells in Patients With Coronary Artery Disease and Renal Insufficiency.
Mehta A, Tahhan AS, Liu C, Dhindsa DS, Nayak A, Hooda A, Moazzami K, Islam SJ, Rogers SC, Almuwaqqat Z, Mokhtari A, Hesaroieh I, Ko YA, Waller EK, Quyyumi AA. Mehta A, et al. JACC Basic Transl Sci. 2020 Aug 12;5(8):770-782. doi: 10.1016/j.jacbts.2020.06.006. eCollection 2020 Aug. JACC Basic Transl Sci. 2020. PMID: 32875168 Free PMC article.
Patients with coronary artery disease and renal insufficiency (RI) (estimated glomerular filtration rate <60 ml/min/1.73 m(2)) are at an increased risk of cardiovascular events. The contribution of regenerative capacity, measured as circulating progenitor cell (CPC) cou …
Patients with coronary artery disease and renal insufficiency (RI) (estimated glomerular filtration rate <60 ml/min/1.73 m(2)) are …
21 results